Replication-Competent VSV for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer and infectious diseases, such as HIV, using vesicular stomatitis viruses (VSV) face challenges in selectively targeting cancer cells while minimizing toxicity to non-cancerous tissues and efficiently replicating within tumor cells.
Innovation Solution
Designing replication-competent VSV with a nucleic acid molecule encoding VSV N, P, M, and L polypeptides, along with Paramyxovirus F and H polypeptides, specifically measles virus polypeptides, and incorporating a sodium iodide symporter (NIS) and interferon (IFN) to enhance targeting and reduce toxicity, allowing for selective accumulation of iodide in infected cells for imaging and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If VSV is used to treat cancer, then tumor cells can be infected and replicated, but toxicity to non-cancerous tissues increases
Solution Approach 1:
The patent applies local quality by making the VSV replication conditional on the local environment within tumor cells. The virus is engineered to replicate only in cells expressing specific tumor-associated antigens, creating a localized therapeutic effect that spares normal tissues. This is achieved through antigen-specific replication mechanisms that activate viral replication pathways only in the presence of tumor-specific markers.
Solution Approach 2:
The patent employs parameter changes by modifying the viral replication parameters through conditional replication control. The VSV is engineered with altered replication kinetics that are activated only under specific conditions present in tumor cells, such as elevated expression of certain host factors or absence of antiviral responses. This allows the virus to replicate efficiently in tumors while maintaining low replication in normal tissues, thereby reducing toxicity.
2Productivity
If VSV replication is enhanced in tumor cells, then tumor regression is improved, but selectivity for cancer cells decreases
Solution Approach 1:
The patent applies preliminary action by pre-engineering the VSV with built-in selectivity mechanisms before administration. The virus is designed in advance with genetic modifications that confer tumor-specific replication capabilities, such as promoter elements that are active only in tumor cells or deleted genes that are complemented only in the tumor microenvironment. This preliminary design ensures that the virus maintains both high replication efficiency and selectivity without requiring post-administration adjustments.
3Object-affected harmful factors
If VSV is modified to reduce toxicity, then safety is improved, but replication efficiency decreases
Solution Approach 1:
The patent applies dynamics by creating a conditional replication system where the virus exhibits different replication behaviors in different cellular environments. The VSV is engineered with dynamic replication control mechanisms that allow high replication efficiency in tumor cells while automatically reducing replication in normal cells. This dynamic behavior is achieved through regulatory elements that respond to cellular conditions, enabling the virus to adapt its replication rate to the specific tissue environment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified VSV effectively infects and replicates within cancer cells, reducing tumor size and inducing tumor regression while minimizing toxicity to non-cancerous tissues, enabling both imaging and targeted radiotherapy.
Implementation Method 1
incorporating a sodium iodide symporter (NIS) and interferon (IFN) to enhance targeting and reduce toxicity, allowing for selective accumulation of iodide in infected cells for imaging and therapy
Data Source
AI summary
This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.